Saturday 17 October 2026
Export GYRE’s income statement to Excel — free account
Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.
6.08
0.32
−5.00%
Follow GYRE
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
141.20 | 86.43 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 5 | 4 | 8 | — | — | — | 4 | 4 | 2 |
Altman Z-Score |
16.83 | 23.76 | 25.08 | 26.41 | (13.25) | (1.65) | — | 8.65 | (3.81) | (6.50) |
P/S ratio |
5.41 | 9.74 | 13.80 | 5.26 | 3.80 | 5.78 | — | 117.56 | 48.36 | 19.35 |
P/FCF ratio |
0.00 | 0.00 | 87.15 | 98.87 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
8.71 | 5.15 | (2.01) | 9.96 | (26.84) | (5.67) | — | 24.45 | (9.29) | (12.82) |
P/Operating CF |
(112.14) | (373.33) | 466.11 | 13.30 | (1.58) | (5.48) | — | (9.82) | (7.79) | (1.55) |
Beneish M-Score |
(2.02) | (1.20) | (6.80) | 9.51 | — | — | — | — | — | (3.91) |
P/B ratio |
10.59 | 10.46 | 112.28 | 7.79 | 0.68 | 1.59 | — | 0.74 | 1.60 | 0.48 |
Price to Tangible BV |
11.51 | 10.65 | 127.84 | 8.00 | 0.68 | 1.59 | — | 0.74 | 1.60 | 0.48 |
EV/Sales |
4.66 | 9.53 | 13.56 | 5.07 | (1.87) | 2.24 | — | (35.09) | 16.39 | (23.22) |
EV/EBITDA |
38.79 | 56.80 | 0.00 | 52.54 | 0.16 | 0.00 | — | 0.78 | 0.00 | 0.46 |
EV/Operating CF |
537.99 | (276.90) | 59.40 | 50.84 | 0.16 | (0.85) | — | 0.93 | (0.84) | 0.50 |
EV/FCF |
(615.37) | (158.25) | 85.58 | 95.36 | 0.16 | (0.85) | — | 0.91 | (0.84) | 0.57 |
Quick Ratio |
4.58 | 2.64 | 2.49 | 3.46 | 3.44 | 4.65 | 3.18 | 25.03 | 4.32 | 1.66 |
Current Ratio |
5.60 | 3.32 | 2.85 | 4.06 | 3.63 | 5.03 | 3.32 | 25.83 | 4.48 | 1.71 |
Net Debt/EBITDA |
(3.74) | (1.50) | 0.51 | (2.44) | 0.53 | 1.39 | 1.35 | 3.57 | 1.51 | 0.86 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 12.87% | 50.94% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 1.21 |
Asset Turnover |
0.80 | 0.87 | 1.13 | 1.46 | 0.10 | 0.22 | 0.00 | 0.00 | 0.03 | 0.01 |
Operating CF/Net income |
0.20 | (0.30) | (0.28) | 4.64 | 0.95 | 0.98 | 0.79 | 0.95 | 0.78 | 1.09 |
Capex/Depreciation |
(0.75) | (1.72) | (7.11) | (4.43) | (2.89) | (1.93) | (0.44) | (2.52) | (0.13) | 5.39 |
Interest Coverage |
— | — | — | 17.14 | (2,253.69) | (102.26) | (26.70) | — | — | — |
| 4.18% | 21.51% | (215.71%) | 4.06% | (150.11%) | (77.89%) | (58.61%) | (39.88%) | (108.92%) | (71.35%) | |
| 3.45% | 9.99% | (92.34%) | 3.28% | (116.85%) | (58.16%) | (49.38%) | (36.56%) | (65.75%) | (31.49%) | |
ROIC |
7.99% | 14.08% | (93.45%) | 12.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
4.67% | 17.48% | (153.70%) | 4.18% | (229.70%) | (77.95%) | (81.78%) | (25.13%) | (83.25%) | (105.91%) |
Average Days of Receivables |
98.02 | 85.52 | 52.92 | 61.15 | 90.43 | 57.73 | 0.00 | 0.00 | 0.00 | 28.36 |
Research and Development Expense of Revenue |
11.75% | 11.37% | 85.40% | 16.31% | 938.80% | 252.89% | 0.00% | 357,900.00% | 1,261.98% | 2,895.99% |
Selling, General and Administrative Expense of Revenue |
73.75% | 69.61% | 66.83% | 70.00% | 258.42% | 77.24% | 0.00% | 205,900.00% | 981.63% | 2,321.30% |
Intangible Assets out of Total Assets |
0.04 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6.14% | 0.79% | 6.42% | 13.07% | 46.40% | 17.31% | 0.00% | 43,433.33% | 84.77% | 159.15% |
Graham Net Nets |
0.19 | 0.04 | 0.01 | 0.07 | 1.32 | 0.58 | — | 1.34 | 0.62 | 2.01 |
Graham Number |
0.87 | 1.91 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
0.71% | 1.16% | (12.78%) | (44.04%) | (315.23%) | (44.83%) | — | (33.57%) | (65.38%) | (218.29%) |
Free Cash Flow Yield |
(0.14%) | (0.62%) | 1.15% | 1.01% | (303.37%) | (45.69%) | — | (32.68%) | (40.55%) | (212.07%) |
Revenue per Share |
1.30 | 1.24 | 1.72 | 1.61 | 3.59 | 16.38 | 0.00 | 0.01 | 4.46 | 7.67 |
Operating CF per Share |
0.01 | (0.04) | 0.39 | 0.17 | (40.98) | (43.03) | (54.47) | (38.17) | (87.30) | (355.23) |
Capex per Share |
(0.02) | (0.03) | (0.12) | (0.08) | (0.41) | (0.21) | (0.08) | (0.50) | (0.10) | 40.31 |
Free Cash Flow per Share |
(0.01) | (0.07) | 0.27 | 0.09 | (41.39) | (43.24) | (54.55) | (38.68) | (87.40) | (314.92) |
Cash per Share |
0.59 | 0.31 | 0.51 | 0.40 | 22.92 | 62.03 | 96.00 | 160.66 | 165.39 | 702.54 |
Shareholders Equity per Share |
1.59 | 1.16 | 1.19 | 1.14 | 20.10 | 59.47 | 85.35 | 160.35 | 134.74 | 309.06 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.59 | 1.16 | 1.19 | 1.14 | 20.10 | 59.47 | 85.35 | 160.35 | 134.74 | 309.06 |
Free Cash Flow |
(0.88) | (6.37) | 17.97 | 5.68 | (84.59) | (55.31) | (43.68) | (28.93) | (19.96) | (16.38) |
Working Capital |
84.08 | 45.27 | 37.17 | 37.41 | 37.31 | 71.71 | 67.17 | 119.19 | 30.37 | 15.56 |
Capital Expenditures |
(1.89) | (2.73) | (7.92) | (5.00) | (0.84) | (0.27) | (0.06) | (0.38) | (0.02) | 2.10 |
Net Current Asset Value |
78.52 | 37.78 | 19.16 | 37.12 | 36.90 | 70.73 | 65.85 | 119.02 | 30.37 | 15.50 |
EV/EBIT |
47.30 | 62.38 | 0.00 | 58.98 | 0.16 | 0.00 | — | 0.78 | 0.00 | 0.45 |
Capex to Sales |
0.02 | 0.03 | 0.07 | 0.05 | 0.11 | 0.01 | 0.00 | 62.67 | 0.02 | (5.25) |
Price to Operating Income |
54.91 | 63.70 | 0.00 | 61.15 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.11 | 0.07 | 0.05 | 0.06 | 0.30 | 0.32 | 0.48 | 0.39 | 0.63 | 0.88 |
Cash ROIC |
(0.45%) | (5.09%) | 16.05% | 5.83% | (96.20%) | (35.59%) | (30.08%) | (12.05%) | (27.11%) | (22.74%) |
Accounts Receivable Turnover |
4.16 | 5.13 | 6.76 | 10.79 | 2.86 | 2.29 | 0.00 | 0.00 | 0.00 | 1.53 |
Accounts Payable Turnover |
46.69 | 16.78 | 19.44 | 1.47 | 1.20 | 1.79 | 0.05 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.66 | 0.73 | 0.89 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
8.36 | 10.15 | 27.95 | 9.29 | 317.47 | 236.26 | 10,697.50 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
685.45 | 595.52 | 337.05 | 466.21 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
28.04 | 20.62 | 16.79 | 9.48 | 2.57 | 9.16 | 7.52 | — | — | 0.26 |
Average Payables |
0.12 | 0.23 | 0.24 | 3.27 | 6.18 | 5.11 | 2.76 | 1.00 | 0.79 | 0.89 |
Average Inventory |
8.25 | 5.31 | 5.20 | — | — | — | — | — | — | — |
Average Assets |
145.77 | 120.97 | 100.65 | 70.21 | 75.25 | 96.70 | 111.74 | 82.22 | 38.80 | 53.81 |
Average Common Equity |
120.34 | 56.18 | 43.08 | 56.65 | 58.58 | 72.20 | 94.14 | 75.36 | 23.42 | 23.75 |
Columns are period end dates